Supernus Pharmaceuticals Celebrates Milestone in ADHD Treatment with Qelbree's Five-Year Anniversary

Qelbree was first approved by the U.S. Food and Drug Administration (FDA) in April 2021, specifically for pediatric patients aged 6 to 17. The following year, in April 2022, the FDA expanded its approval to include adults aged 18 years and older, making Qelbree the first non-stimulant treatment option for adults in two decades. This expansion acknowledges the evolving understanding of ADHD, with research indicating that approximately 90% of children with ADHD continue to experience symptoms into adulthood.

Since its launch, Qelbree has gained significant traction, with over 3 million total prescriptions filled and more than 1 million prescriptions filled in 2025 alone. This widespread adoption underscores the importance of offering healthcare providers and patients a reliable, non-stimulant option for managing ADHD symptoms.

Qelbree is distinguished by its unique pharmacodynamic profile, influencing key chemical messengers in the brain in various ways. The medication helps to increase norepinephrine levels and acts as a partial agonist at the serotonin (5-HT2C) receptor. This multimodal approach makes it the first and only non-stimulant ADHD treatment to achieve such a profile.

In January 2025, the FDA approved updates to Qelbree's labeling to include additional pharmacodynamic data and information regarding lactation, making it the first ADHD treatment to meet the FDA's post-marketing requirements laid out in 2019 regarding Clinical Lactation Studies. This labeling update further solidifies Qelbree's commitment to providing comprehensive care options for patients.

Supernus Pharmaceuticals has a longstanding legacy of over 25 years in ADHD research and treatment, and the company continues to prioritize support for the ADHD community. Recent initiatives, such as the campaigns *You, Me & Qelbree* and *Ms. Represented*, aim to empower individuals living with ADHD and educate the public on how symptoms can manifest differently across genders. These campaigns also highlight the vital role of support systems, such as friends and family, in managing ADHD.

Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, emphasized the importance of flexible treatment options in his statement: “ADHD care is ever-changing, but one thing remains constant: the need for flexible treatment options that enable healthcare providers and patients to make truly tailored decisions. For the past five years, Qelbree has delivered on this need, standing as a trusted choice for many.”

As Supernus Pharmaceuticals celebrates this significant five-year milestone, it remains focused on its commitment to innovate and expand treatment options for CNS diseases. With Qelbree's substantial market impact and continued support for the ADHD community, Supernus is well-positioned to further enhance patient care and treatment outcomes.

For more information on Qelbree and Supernus Pharmaceuticals, visit www.qelbree.com and www.supernus.com.